# MHC Class II Epitope Prediction Report

## Summary

Total MHC Class II epitopes predicted: 11322
High-scoring epitopes (score > 0.7): 10988
Promiscuous epitopes (â‰¥3 alleles): 11322
MHC Class II alleles analyzed: 19

## Population Coverage (MHC Class II)

**World**: 80.7%

## Top 20 MHC Class II Epitopes

| Rank | Peptide | Length | Score | Allele Count | Best Allele | IC50 (nM) |
|------|---------|--------|-------|--------------|-------------|----------|
| 1 | GVYYPDKVFRSSVLH | 15 | 0.991 | 19 | HLA-DRB1*03:01 | 1.0 |
| 2 | STFKCYGVSPTKLNDL | 16 | 0.991 | 19 | HLA-DRB1*01:01 | 1.0 |
| 3 | GDEVRQIAPGQTGKIA | 16 | 0.990 | 19 | HLA-DRB1*01:01 | 1.0 |
| 4 | IRGDEVRQIAPGQTG | 15 | 0.990 | 19 | HLA-DRB1*03:01 | 1.0 |
| 5 | KVFRSSVLHSTQDLF | 15 | 0.989 | 19 | HLA-DRB1*01:01 | 1.0 |
| 6 | IDRLITGRLQSLQTYV | 16 | 0.988 | 19 | HLA-DRB1*04:01 | 1.0 |
| 7 | SFSTFKCYGVSPTKLN | 16 | 0.988 | 19 | HLA-DRB1*01:01 | 1.0 |
| 8 | YGSFCTQLNRALTGI | 15 | 0.988 | 19 | HLA-DRB1*01:01 | 1.0 |
| 9 | LIANQFNSAIGKIQD | 15 | 0.988 | 19 | HLA-DRB1*01:01 | 1.0 |
| 10 | SNNLDSKVGGNYNYLY | 16 | 0.987 | 19 | HLA-DRB1*01:01 | 1.0 |
| 11 | IAQYTSALLAGTITSG | 16 | 0.987 | 19 | HLA-DRB1*03:01 | 1.0 |
| 12 | YGVSPTKLNDLCFTN | 15 | 0.987 | 19 | HLA-DRB1*01:01 | 1.0 |
| 13 | WIFGTTLDSKTQSLLI | 16 | 0.987 | 19 | HLA-DRB1*01:01 | 1.0 |
| 14 | KSNLKPFERDISTEIY | 16 | 0.987 | 19 | HLA-DRB1*01:01 | 1.0 |
| 15 | FELLHAPATVCGPKKS | 16 | 0.987 | 19 | HLA-DRB1*03:01 | 1.0 |
| 16 | VYSTGSNVFQTRAGCL | 16 | 0.987 | 19 | HLA-DRB1*01:01 | 1.0 |
| 17 | YSNNSIAIPTNFTIS | 15 | 0.987 | 19 | HLA-DRB1*03:01 | 1.0 |
| 18 | QYTSALLAGTITSGW | 15 | 0.986 | 19 | HLA-DRB1*01:01 | 1.0 |
| 19 | SSSGWTAGAAAYYVG | 15 | 0.986 | 19 | HLA-DRB1*01:01 | 1.0 |
| 20 | ASFSTFKCYGVSPTKL | 16 | 0.986 | 19 | HLA-DRB1*01:01 | 1.0 |

## MHC Class II Allele Analysis

| Allele | Strong Binders | Weak Binders | Total Binders |
|--------|----------------|--------------|---------------|
| HLA-DRB1*01:01 | 10884 | 426 | 11310 |
| HLA-DRB1*03:01 | 10490 | 798 | 11288 |
| HLA-DRB1*04:01 | 10764 | 542 | 11306 |
| HLA-DRB1*07:01 | 11015 | 299 | 11314 |
| HLA-DRB1*08:01 | 9878 | 1373 | 11251 |
| HLA-DRB1*09:01 | 9879 | 1369 | 11248 |
| HLA-DRB1*11:01 | 9922 | 1332 | 11254 |
| HLA-DRB1*12:01 | 9874 | 1360 | 11234 |
| HLA-DRB1*13:01 | 9910 | 1336 | 11246 |
| HLA-DRB1*15:01 | 11129 | 193 | 11322 |
| HLA-DRB1*16:01 | 9907 | 1344 | 11251 |
| HLA-DQB1*02:01 | 9880 | 1378 | 11258 |
| HLA-DQB1*03:01 | 9919 | 1324 | 11243 |
| HLA-DQB1*05:01 | 9861 | 1369 | 11230 |
| HLA-DQB1*06:01 | 9879 | 1368 | 11247 |
| HLA-DPB1*01:01 | 9867 | 1385 | 11252 |
| HLA-DPB1*02:01 | 9908 | 1338 | 11246 |
| HLA-DPB1*04:01 | 9876 | 1368 | 11244 |
| HLA-DPB1*05:01 | 9860 | 1382 | 11242 |

## Peptide Length Distribution

- 12 amino acids: 1262 epitopes
- 13 amino acids: 1261 epitopes
- 14 amino acids: 1260 epitopes
- 15 amino acids: 1259 epitopes
- 16 amino acids: 1258 epitopes
- 17 amino acids: 1257 epitopes
- 18 amino acids: 1256 epitopes
- 19 amino acids: 1255 epitopes
- 20 amino acids: 1254 epitopes

## Recommendations for CD4+ T-cell Response

Excellent MHC Class II epitope landscape identified. Strong potential for robust CD4+ T-cell responses.

Key considerations for CD4+ T-cell vaccine design:
1. Include promiscuous epitopes for broad population coverage
2. Combine with MHC Class I epitopes for comprehensive immune response
3. Consider epitope spacing and linker design in vaccine constructs
4. Validate with CD4+ T-cell activation assays
5. Assess cytokine production profiles (Th1/Th2/Th17)
